Open AccessVaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Author(s) -
Kathryn E. Stephenson,
Kshitij Wagh,
Bette T. Korber,
Dan H. Barouch
Publication year - 2020
Publication title -
annual review of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 18.301
H-Index - 301
eISSN - 1545-3278
pISSN - 0732-0582
DOI - 10.1146/annurev-immunol-080219-023629
Subject(s) - immunology , pandemic , human immunodeficiency virus (hiv) , biology , clinical trial , immunization , virology , aids vaccines , hiv vaccine , antibody , active immunization , covid-19 , medicine , vaccine trial , bioinformatics , disease , infectious disease (medical specialty)
Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.